The global drug-eluting balloon catheters market size was recorded at USD 1.3 billion in 2021 and is estimated to hit around USD 5.4 billion by 2030, growing at a registered CAGR of 17.14% during the forecast period from 2022 to 2030.
The industry is anticipated to grow as a result of increasing demand for minimally invasive procedures and technological developments in drug-coated balloon catheters. The market share has been significantly impacted by the increase in the elderly population. Additionally, older people are shown to have a larger chance of health issues, making them more vulnerable to illnesses including peripheral and cardiovascular disorders. Balloon catheters with drug-eluting technology help cure and repair these issues. The use of drug-eluting balloon catheters helps patients avoid restenosis and treat coronary atherosclerosis. Thus, it is anticipated that the aforementioned factors will propel the market demand for drug-eluting balloon catheters.
The development of sophisticated drug-eluting balloon catheters for minimally invasive operations and other manufacturing technical developments are anticipated to fuel market growth over the anticipated timeframe. The use of drug-eluting balloon catheters has been encouraged by the rise in patients with atherosclerosis, obstructive coronary artery disease, peripheral vascular disease, etc., and is expected to fuel market expansion in the upcoming years. Additionally, there is a greater need for technologically improved items in healthcare settings due to the rising frequency of chronic diseases and the demand for minimally invasive surgical treatments. The usage of cutting-edge products for surgeries has increased life expectancy and sped up diagnostic processes among the elderly population base, which has fueled market expansion in recent years. To improve medicine delivery, market players are concentrating on creating cost-efficient, accurate, and effective drug-eluting balloon catheters. This effort will support the market growth of drug-eluting balloon catheters over the forecast period.
The usage of drug-eluting catheters, which are often utilised for drug administration in critical instances during surgical procedures linked to cardiovascular illnesses, decreased during the COVID-19 pandemic. Heart disease emergency and general patients experienced a substantial setback that somewhat impacted product adoption. In over 8 nations throughout the world, endovascular therapy was rejected by 32%, according to a report released in March 2020. However, the number of CAD treatments is anticipated to increase once more in the near future because to the increasing number of patients with cardiovascular disorders.
Report Scope of the Drug-Eluting Balloon Catheters Market
|Market Size in 2022||USD 1.52 Billion|
|Market Size by 2030||USD 5.4 Billion|
|Growth Rate from 2022 to 2030||CAGR of 17.14%|
|Forecast Period||2022 to 2030|
Key Market Drivers
Growing prevalence of peripheral and cardiovascular diseases
Growing geriatric population
Key Market Challenges
Key Market Opportunities
The market is divided into two product categories: drug-eluting balloon catheters for peripheral vascular disease and coronary artery disease. The majority market share of drug-eluting balloon catheters for the peripheral vascular disease was held by this segment in 2021, and it is anticipated to grow at a 10.7% CAGR through 2030 as more healthcare facilities and medical professionals adopt cutting-edge products to carry out intricate interventional procedures. These peripheral vascular balloon catheters aid in the delivery of medications, restrict the proliferation of vascular smooth muscle cells during neointimal formation and guard against restenosis, all of which improve patient safety during surgical procedures.
One of the key factors influencing increased product usage is the rising incidence of atherosclerosis in adults. Additionally, nearly 27 million people with atherosclerosis were diagnosed across Europe and North America in 2019. Due to advantages such as lower procedure costs, fewer post-operative complications, and shorter nursing care times, the usage of drug-eluting balloon catheters for vascular illnesses has grown dramatically in recent years. These advantages are anticipated to fuel segmental expansion in the years to come. The use of vascular catheters was approximately 54% worldwide in 2019, according to a study that was published in the journal BMC Nephrology.
On the basis of end-use, the hospital and clinics segment held a dominant market share in 2021 owing to the increasing number of in-patient admissions in hospitals for catheterization procedures along with a surging preference for minimally invasive procedures is anticipated to spur the market demand. A few of the reasons driving the market expansion are the increase in vascular and urological disorders, arrhythmia, etc., as well as the accessibility of highly qualified medical and healthcare experts.
A large hospital network will be established as a result of the focus on developing health infrastructure in emerging nations, which will raise the acceptance rate of products in the years to come. Therefore, an increase in the prevalence of chronic diseases and an increase in hospital admissions are predicted to drive the market share for drug-eluting balloon catheters during the course of the estimated analysis period.
Drug-Eluting Balloon Catheters Market Share, By Region, 2021 (%)
|Regions||Revenue Share in 2021 (%)|
North America has dominated the drug-eluting balloons catheters market with 34.8% revenue share in 2021. The main drivers propelling the growth of the market in North America are the favorable reimbursement environment in the U.S, the rising preference for minimally invasive procedures, and the staggering number of surgeries. Additionally, rising public awareness of the need for surgical procedures to address difficulties with chronic diseases and injuries is fueling market expansion.
There are a number of factors, including the rising incidence of cardiovascular diseases such coronary artery disease, heart valve disease, arrhythmia, heart failure, peripheral disorders, and renal failure, among others. For instance, the Center for Disease Control and Prevention (CDC) reported that approximately 18.2 million adults had coronary artery disease in 2020, which was responsible for around 2 deaths for every 10 patients. Additionally, the NCBI reports that more than 1 million cardiac catheterization operations are carried out annually in the United States. People's changing lifestyles in the nation, such as the rise in obesity prevalence, bad diets, and excessive alcohol usage, have had a substantial impact on their health. Cardiovascular disorders are one of the main causes of death in the U.S, according to the World Health Organization (WHO). It is anticipated that the rising disease prevalence will increase the demand for drug-eluting balloon catheters. The country's market growth is also anticipated to be aided by the rising hospitalization rate and the growing elderly population base. Additionally, the market value and adoption rate of drug-eluting balloon catheters will increase due to the presence of significant market participants in the area.
Over the projected period, the Asia Pacific region is anticipated to increase at the fastest rate. This can be ascribed to a rise in healthcare spending as well as an increase in the prevalence of cardiovascular disorders. According to Biomedcentral, cardiovascular disease affects one in every five persons in China. Furthermore, it is anticipated that the market in the region will be driven by an aging population in nations like Japan and China and rising disposable income. The expansion of the industry in the area is also being aided by the rise of health tourism in emerging countries.
Key Market Players
Segments Covered in the Report
(Note*: We offer reports based on sub-segments as well. Kindly, let us know if you are interested)
By Raw Material
No cookie-cutter, only authentic analysis – take the 1st step to become an Precedence Research client